Bristol Myers Squibb (CELG-RI) Other Non-Current Liabilities (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Other Non-Current Liabilities for 18 consecutive years, with $4.3 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Other Non-Current Liabilities fell 12.16% year-over-year to $4.3 billion; the TTM figure through Jun 2026 stood at $4.3 billion (down 12.16% YoY), while the FY2025 annual figure was $5.0 billion, up 12.84% from the prior year.
• Other Non-Current Liabilities fell to $4.3 billion in Q2 2026 per CELG-RI's latest filing, from $4.9 billion in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $7.3 billion in Q1 2022 and bottomed at $4.3 billion in Q2 2026.
• Historically, Other Non-Current Liabilities has averaged $5.7 billion across 5 years, with a median of $5.7 billion in 2023.
• On a YoY basis, Other Non-Current Liabilities climbed as much as 15.46% in 2025 and fell as far as 33.5% in 2025.
• Bristol Myers Squibb's Other Non-Current Liabilities stood at $6.6 billion in 2022, then dropped by 2.56% to $6.4 billion in 2023, then sank by 30.4% to $4.5 billion in 2024, then rose by 12.84% to $5.0 billion in 2025, then decreased by 13.92% to $4.3 billion in 2026.
• Business Quant data shows CELG-RI's Other Non-Current Liabilities at $4.3 billion in Q2 2026, $4.9 billion in Q1 2026, and $5.0 billion in Q4 2025.